Three Biopharmaceutical Organizations Award $1.7 Million in Studies to eResearchTechnology for Cardiac Safety Monitoring and Inf
April 05 2004 - 9:05AM
PR Newswire (US)
Three Biopharmaceutical Organizations Award $1.7 Million in Studies
to eResearchTechnology for Cardiac Safety Monitoring and
Information Distribution Services Awards Advance Market Penetration
in Early and Late Stage Development PHILADELPHIA, April 5
/PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT), , a
leading provider of centralized electrocardiographic (ECG)
collection and interpretation services, announced today that it has
received agreements for about $1.7 million in cardiac safety
monitoring and services from two fast growing biotechnology
organizations and a mid-market biopharmaceutical organization for
three drug candidates in clinical development. The agreements cover
two extensive Phase I studies and two Phase III studies that will
be conducted at more than 100 sites in North America and Europe.
eRT will provide comprehensive support including the provision,
training and ongoing assistance required for effective use of 100
standing 12- lead ECG machines and more than 60 digital 12-lead
Holter recorders, which are designed to facilitate 24-hour digital
recording of cardiac safety data that is subsequently provided to
eRT for analysis. eRT will perform digital collection, measurement,
interpretation, review, and distribution of cardiac safety data
through its EXPeRT workflow enabled data handling technology, the
first solution in production that was designed explicitly to meet
emerging international regulatory guidance and technical standards.
"eRT's vast experience in providing cardiac safety services across
all phases of clinical development will drive value for the fast
growing sponsors of these diverse trials, which range from a
Thorough Phase I ECG Study, to a significant routine Phase I study,
to two massively distributed Phase III trials," said Scott
Grisanti, senior vice president of business development and chief
marketing officer at eRT. "We continue to advance our market
penetration with the signing of two sponsors that represent new
customers for eRT as well as expanding our role with an existing
client in its effort to bring a novel therapy to market." Based in
Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/)
is a provider of technology and services to the pharmaceutical,
biotechnology and medical device industries on a global basis. The
company is a market leader in providing centralized core-diagnostic
electrocardiographic (ECG) technology and services to evaluate
cardiac safety in clinical development. The company is also a
leader in providing technology and services to streamline the
clinical trials process by enabling its customers to automate the
collection, analysis, and distribution of clinical data in all
phases of clinical development. Statements included in this release
may constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the
company's ability to obtain new contracts and accurately estimate
net revenues due to variability in size, scope and duration of
projects, and internal issues in the sponsoring client. The
sponsors may cancel these agreements at their sole discretion. As a
result, actual results may differ materially from any financial
outlooks stated herein. Further information on potential factors
that could affect the company's financial results can be found in
the company's Reportson Forms 10-K and 10-Q filed with the
Securities and Exchange Commission. DATASOURCE:
eResearchTechnology, Inc. CONTACT: Joan Sterlacci of
eResearchTechnology, +1-908-203-6473; or Matt Hayden of Hayden
Communications, +1-858-456-4533, for eResearchTechnology Web site:
http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about East Resources Acquisition Company (NASDAQ): 0 recent articles
More Eresearch Tech (MM) News Articles